Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Mar 21;11(1):51.
doi: 10.1038/s41531-025-00897-1.

Digital gait biomarkers in Parkinson's disease: susceptibility/risk, progression, response to exercise, and prognosis

Affiliations
Review

Digital gait biomarkers in Parkinson's disease: susceptibility/risk, progression, response to exercise, and prognosis

Martina Mancini et al. NPJ Parkinsons Dis. .

Abstract

This narrative review examines the utility of gait digital biomarkers in Parkinson's disease (PD) research and clinical trials across four contexts: disease susceptibility/risk, disease progression, response to exercise, and fall prediction. The review of the literature to date suggests that upper body characteristics of gait (e.g., arm swing, trunk motion) may indicate susceptibility/risk of PD, while pace aspects (e.g., gait speed, stride length) are informative for tracking disease progression, exercise response, and fall likelihood. Dynamic stability aspects (e.g., trunk regularity, double-support time) worsen with disease progression but can improve with exercise. Gait variability emerges as a sensitive biomarker across all 4 contexts but with low specificity. The lack of standardized gait testing protocols and the lack of a minimum set of quantified digital gait biomarkers limit data harmonization across studies. Future studies, using a commonly agreed upon protocol, could be used to demonstrate the utility of specific gait biomarkers for clinical practice.

PubMed Disclaimer

Conflict of interest statement

Competing interests: Fay Horak is an employee of APDM Wearable Technologies—a Clario company that may have a commercial interest in the results of this research and technology. This potential conflict has been reviewed and managed by OHSU. All other authors declare no Competing Financial or Non-Financial Interests.

Figures

Fig. 1
Fig. 1. Stereotypical gait pattern in PD and independent domains of gait with their associated digital gait metrics.
RoM Range of Motion, CoV Coefficient of Variation, SD standard deviation.
Fig. 2
Fig. 2
Context of use for gait biomarkers for Parkinson’s disease summarized in this review.

References

    1. Deng, K. et al. Heterogeneous digital biomarker integration out-performs patient self-reports in predicting Parkinson’s disease. Commun. Biol.5, 58, 10.1038/s42003-022-03002-x (2022). - PMC - PubMed
    1. Stephenson, D., Badawy, R., Mathur, S., Tome, M. & Rochester, L. Digital progression biomarkers as novel endpoints in clinical trials: a multistakeholder perspective. J. Parkinsons Dis.11, S103–S109, 10.3233/JPD-202428 (2021). - PMC - PubMed
    1. Gerlach, M. et al. Biomarker candidates of neurodegeneration in Parkinson’s disease for the evaluation of disease-modifying therapeutics. J. Neural Transm.119, 39–52, 10.1007/s00702-011-0682-x (2012). - PMC - PubMed
    1. Horak, F. B. & Mancini, M. Objective biomarkers of balance and gait for Parkinson’s disease using body-worn sensors. Mov. Disord.28, 1544–1551, 10.1002/mds.25684 (2013). - PMC - PubMed
    1. Coravos, A., Khozin, S. & Mandl, K. D. Developing and adopting safe and effective digital biomarkers to improve patient outcomes. npj Digit. Med.2, 14, 10.1038/s41746-019-0090-4 (2019). - PMC - PubMed

LinkOut - more resources